P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES

Detalles Bibliográficos
Autores principales: KHOO, C. M., SONG, X., WU, Q., COX, G. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430101/
http://dx.doi.org/10.1097/01.HS9.0000846172.64321.0a
_version_ 1784779657423355904
author KHOO, C. M.
SONG, X.
WU, Q.
COX, G. F.
author_facet KHOO, C. M.
SONG, X.
WU, Q.
COX, G. F.
author_sort KHOO, C. M.
collection PubMed
description
format Online
Article
Text
id pubmed-9430101
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94301012022-08-31 P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES KHOO, C. M. SONG, X. WU, Q. COX, G. F. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430101/ http://dx.doi.org/10.1097/01.HS9.0000846172.64321.0a Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
KHOO, C. M.
SONG, X.
WU, Q.
COX, G. F.
P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES
title P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES
title_full P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES
title_fullStr P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES
title_full_unstemmed P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES
title_short P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES
title_sort p822: a phase 1 single ascending dose study of can106, a long-acting anti-c5 complement monoclonal antibody in clinical development for pnh and other complement-mediated diseases
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430101/
http://dx.doi.org/10.1097/01.HS9.0000846172.64321.0a
work_keys_str_mv AT khoocm p822aphase1singleascendingdosestudyofcan106alongactingantic5complementmonoclonalantibodyinclinicaldevelopmentforpnhandothercomplementmediateddiseases
AT songx p822aphase1singleascendingdosestudyofcan106alongactingantic5complementmonoclonalantibodyinclinicaldevelopmentforpnhandothercomplementmediateddiseases
AT wuq p822aphase1singleascendingdosestudyofcan106alongactingantic5complementmonoclonalantibodyinclinicaldevelopmentforpnhandothercomplementmediateddiseases
AT coxgf p822aphase1singleascendingdosestudyofcan106alongactingantic5complementmonoclonalantibodyinclinicaldevelopmentforpnhandothercomplementmediateddiseases

Ejemplares similares